Table 2 Predictive role of exosomal cargo in tumor drug resistance

Colorectal cancer

miR-92a-3p (5-Fu/Oxaliplatin)

[55]

miR–125b (mFOLFOX6)

[139]

lncRNA UCA1 (Cetuximab)

[137]

A panel of miR-21-5p, miR-1246, miR1229-5p and miR-96-5p (oxaliplatin and 5-fluorouracil)

[138]

Prostate cancer

ITGB4 and Vinculin (Taxane)

[141]

AR-V7 (Hormonal Therapy)

[144]

P-glycoprotein (Docetaxel)

[39]

CD44v8-10 mRNA (Docetaxel)

[140]

MDR-1, MDR-3, endophilin-A2, and PABP4 (Docetaxel)

[147]

miR-1290 (Docetaxel)

[148]

miR-34a (Docetaxel)

[142]

Breast cancer

Survivin (Paclitaxel)

[76]

TRPC5

[145]

TK1 and CDK9 mRNA (CDK4/6 inhibitors)

[149]

lncRNA–SNHG14 (Trastuzumab)

[73]

lncRNA AFAP1-AS1 (Trastuzumab)

[62]

RNA H19 (Doxorubicin)

[150]

GSTP1 (Adriamycin)

[136]

Multiple myeloma

PSMA3 and lncPSMA3-AS1 (Bortezomib)

[151]

Ovarian cancer

Plasma gelsolin (pGSN)

[152]

Pancreatic cancer

EphA2 (Gemcitabine)

[153]

miR-155 (Gemcitabine)

[154]

Head and neck cancer

miR-196a (Cisplatin)

[155]

Lung cancer

miR-222-3p (Gemcitabine)

[156]

miR-146a-5p (Cisplatin)

[157]

miR-21 (Cisplatin)

[158]

miR-425-3p (Platinum-based chemotherapy)

[8, 60]

lncRNA RP11–838N2.4 (Erlotinib)

[159]

Melanoma

PDGFR-B (Vemurafenib)

[160]

Glioblastoma

miR-1238 (Temozolomide)

[161]

miR-151a (Temozolomide)

[82]

MET and p-MET (Temozolomide)

[75]

lncSBF2-AS1 (Temozolomide)

[81]

Gestational trophoblastic neoplasia

miR-219a-5p (Methotrexate)

[162]

Diffuse large B-cell lymphoma

miR-146a

[163]

miR-99a-5p and miR-125b-5p (R-CHOP regimen)

[164]

Renal cell carcinoma

lncARSR (Sunitinib)

[72]